Feladilimab
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab) ; GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer[1].
Product Specifications
CAS Number
2252518-85-5
Product Name Alternative
Anti-ICOS/CD278 Reference Antibody (feladilimab) ; GSK3359609
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/feladilimab.html
Purity
99.255
Solubility
10 mM in DMSO
Smiles
[Feladilimab]
Molecular Weight
(145.52 kDa)
References & Citations
[1]Offidani M, et al. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021 Jun 2;15:2401-2415.|[2]Steeghs N, et al. Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clin Transl Sci. 2022 Nov;15 (11) :2625-2639.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
